What is Zacks Research’s Forecast for PBYI FY2025 Earnings?

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Equities research analysts at Zacks Research increased their FY2025 earnings per share (EPS) estimates for Puma Biotechnology in a research report issued to clients and investors on Wednesday, January 22nd. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.31 per share for the year, up from their prior forecast of $0.28. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at $0.12 EPS.

Several other equities analysts have also commented on PBYI. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Monday, December 23rd.

Puma Biotechnology Stock Up 0.7 %

Shares of NASDAQ PBYI opened at $2.98 on Monday. The stock has a market cap of $146.29 million, a P/E ratio of 6.21 and a beta of 1.10. The business’s fifty day simple moving average is $3.07 and its 200-day simple moving average is $2.98. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Puma Biotechnology has a 12-month low of $2.22 and a 12-month high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The company had revenue of $80.50 million for the quarter, compared to analysts’ expectations of $71.32 million. During the same period in the prior year, the firm earned $0.12 earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PBYI. Frazier Life Sciences Management L.P. grew its stake in Puma Biotechnology by 8.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock worth $9,984,000 after acquiring an additional 246,264 shares during the period. American Century Companies Inc. lifted its holdings in shares of Puma Biotechnology by 98.5% during the 2nd quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after acquiring an additional 366,653 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Puma Biotechnology by 6.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 605,977 shares of the biopharmaceutical company’s stock valued at $1,975,000 after acquiring an additional 37,684 shares in the last quarter. State Street Corp lifted its holdings in Puma Biotechnology by 17.0% in the 3rd quarter. State Street Corp now owns 601,542 shares of the biopharmaceutical company’s stock worth $1,534,000 after buying an additional 87,504 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Puma Biotechnology by 3.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 368,455 shares of the biopharmaceutical company’s stock worth $940,000 after buying an additional 13,941 shares in the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Alan H. Auerbach sold 33,841 shares of Puma Biotechnology stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $106,599.15. Following the completion of the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. This trade represents a 0.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $29,726.55. Following the sale, the insider now owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. The trade was a 7.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 23.70% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.